PIPELINE
[IL2102] SOS1 Inhibitor for RAS Driven Cancers
[IL2102] SOS1 Inhibitor for RAS Driven Cancers • Potentially best-in-class, orally available, small molecule SOS1 inhibitor for any RAS driven cancers which has shown strong activity against various KRAS mutants and wild types including KRAS G12C, G12D, G12V and KRAS G13C. • …
[IL2106] Cyclin-K Degrader for Solid Tumors
[IL2106] Cyclin-K Degrader for Solid Tumors • Potentially first-in-class, orally available, small molecule Cyclin-K Degrader with strong anti-cancer activities for difficult cancers including those without identifiable drivers. • We are developing a potent Cyclin-K Degrader …
[IL2112] CXCR 7 Agonist for Neurodegenerative Diseases
[IL2112] CXCR 7 Agonist for Neurodegenerative Diseases • Potentially first-in-class, orally available, small molecule CXCR7 agonist with a high permeability for the blood–brain barrier (BBB) for various neurodegenerative diseases such as ALS, Multiple sclerosis (MS), Parkinson…
[IL2112] CXCR 7 Agonist for Fibrotic Diseases
[IL2112] CXCR 7 Agonist for Fibrotic Diseases • First-in-class, orally available, small molecule, chemokine receptor type 7 (CXCR7) agonist for treatment of various fibrotic and autoimmune diseases.• Chemokines play crucial roles in many physiological and pathological process…